Canada clears Intercept blood pathogen inactivator:
This article was originally published in Clinica
Executive Summary
Baxter and Cerus have gained Canadian market approval for what they claim is the first pathogen inactivation system approved in the country for use with platelets intended for transfusion. The Intercept blood system, which was recently approved in Europe (see Clinica No 1029, p 25), is cleared in Canada for use with platelets prepared using the buffy coat method, says Cerus. The firm notes that though Canada currently uses the platelet rich plasma and single donor platelet collection methods, the Canadian Blood Services and Hema Quebec are evaluating the possibility of implementing the buffy coat method. The firms plan to apply in early 2003 for permission to use their system with single-donor platelets.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.